Nkarta (NKTX) Asset Writedowns and Impairment (2023 - 2026)
Nkarta (NKTX) posted quarterly Asset Writedowns and Impairment of $791000.0 for Q3 2025, down 80.71% quarter-over-quarter from $4.1 million in Q2 2023.
Nkarta (NKTX) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Nkarta's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $791000.0 for Q3 2025.
- In Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $791000.0; the TTM figure through Dec 2025 stood at $791000.0 (changed N/A YoY), while the FY2025 annual figure was $791000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $791000.0, down from $4.1 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $4.1 million in Q2 2023, with the low at $791000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.67 Mn |
| Jun 30, 2026 | 5.67 Mn |
| Sep 30, 2025 | 791,000.00 |
| Sep 30, 2025 | 791,000.00 |
| Jun 30, 2023 | 4.10 Mn |
| Jun 30, 2023 | 4.10 Mn |